Metrics as of 10/16/2026, 11:39 AM (Berlin time), refresh in progress.
Castle Biosciences Stock
Castle Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Derek J. Maetzold
- Employees
- 1,002
- Market cap
- $1 B
- IPO
- 25/07/2019
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression…
Castle Biosciences stock: price history
1D
+2.1%
1W
+0.3%
1M
-4.8%
6M
+37.6%
YTD
-13.1%
1Y
+50.2%
2Y
+1.0%
5Y
-46.8%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~49% stronger price swings than usual
Castle Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Castle Biosciences is a specialized diagnostic services provider primarily focused on the examination of dermatological cancers. Through proprietary gene expression profiling (GEP) tests such as DecisionDx-Melanoma and DecisionDx-SCC, the company delivers clinical data to predict the probability of metastasis in patients with melanoma or squamous cell carcinoma. These services are primarily delivered to affected patients through healthcare professionals. The business model is based on providing specialized diagnostic and prognostic tests that support medical treatment decision-making.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- Medium
- Customer concentration
- Unknown
Ask the agents about Castle Biosciences
Analyst assessment of Castle Biosciences
PRICE TARGET LOW
US$35.00
CONSENSUS
US$39.00
MEDIAN
US$40.00
PRICE TARGET HIGH
US$44.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 03/08/2026
Castle Biosciences stock metrics
P/E
-51.25
P/B
2.19
EV/EBITDA
-311.22
RETURN ON EQUITY
-0.4%
NET MARGIN
-2.0%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.9%
FLOAT SHARES
27,159,123
AVG. DAILY VOLUME (30D)
348,675
Insider transactions (SEC)
Juvenal Tobin W
MAETZOLD DEREK J
MAETZOLD DEREK J
MAETZOLD DEREK J
MAETZOLD DEREK J
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +2.1%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Castle Biosciences stock
What does Castle Biosciences do?
Castle Biosciences, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Derek J. Maetzold, the company employs around 1,002 people.
The IPO was on 25/07/2019; the stock trades on NASDAQ under the ticker CSTL.
What do analysts say about Castle Biosciences stock?
11 analysts rate the stock, the consensus is Buy (as of 03/08/2026).
The average price target is US$39.00, ranging from US$35.00 to US$44.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Castle Biosciences report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 49% stronger than usual.
Does Castle Biosciences pay a dividend?
No, Castle Biosciences currently does not pay a dividend.
Which stocks are comparable to Castle Biosciences?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Castle Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Castle Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.